Skip to content
Westlake BioPartners
  • People
  • Portfolio
  • About
  • News
  • Contact
Westlake BioPartners
  • People
  • Portfolio
  • About
  • News
  • Contact

Investing in People With Vision

It takes a village to bring life-saving medicines to market, so we invest in entrepreneurs to create companies that turn breakthroughs into treatments for patients in need. 

W Hero Image

We Put People First

Westlake BioPartners is a people-first life science VC firm that crafts companies around world-class entrepreneurs. Immersed in the Los Angeles biotech community we helped catalyze, we’re intentionally scaled to incubate only the most promising companies by complementing their teams with personal attention, hands-on support, and connections to the most impactful innovations of our time. We believe it takes more than just great science to make life-changing medicines and by putting people first, we serve the greatest unmet patient needs.

Get to Know Our People

Our Entrepreneurs Making a Difference

Nancy Whiting, CEO

Nancy Whiting,
CEO

Recludix Pharma

Transforming the lives of people with inflammatory diseases.

Anurag Agarwal,
CEO &
co-founder

Leon Garcia Martinez,
CSO & co-founder

Vedana Therapeutics

Migraine freedom for all patients.

Company We’re Proud to Keep

The Westlake Way

We know people are the first and most valuable asset. Our approach focuses on empowering the right entrepreneurs and guiding them through growth from ideation and preclinical research to clinical and commercial impact for the treatment of patients. We’re intentionally scaled to foster close relationships with our founders, take action instead of offer opinions, and deepen harmonious connections in our entrepreneurial network. By committing to personal attention, we provide each member of our concentrated portfolio with equal and essential access to innovation, capital, and community.

Learn About Our Approach

Happenings in Our Network

Portfolio News

Sundance Biosciences Announces First Patient Dosed in U.S. Phase 2 Clinical Trial of SUN-627 for Progressive Forms of Multiple Sclerosis (MS)

October 22, 2026
Phase 2 trial to evaluate SUN-627, a potent, highly-selective, brain-penetrant, oral...
Read More
Portfolio News

Sundance Biosciences Announces Presentation of Phase 1 Results for SUN-627, a Brain-Penetrant TYK2 Inhibitor for the Treatment of Multiple Sclerosis (MS)

October 21, 2026
SUN-627 demonstrated favorable safety, tolerability, and pharmacokinetics for oral, once-daily dosing...
Read More
Portfolio News
Oorja Bio logo

Oorja Bio Announces Initiation of ORBIT-IPF Phase 2 Clinical Trial Evaluating ORJ-001 for the Treatment of Idiopathic Pulmonary Fibrosis

October 13, 2026
Randomized, placebo-controlled study to evaluate the safety, tolerability, and efficacy in...
Read More
See All the Latest

A Complementary Community

Where our visionary founders seized the opportunity to propel the Los Angeles biotech ecosystem, we’ve continued to build an increasingly symbiotic and ever-evolving community. From finding the right entrepreneurs to spearhead company formation, to scaling science through phase-appropriate R&D resources, our network provides unique complementary connections. Drawing from these roots, we support people making medical breakthroughs in California and beyond.

Thinking of the next breakthrough?

Join Our Community
  • People
  • Portfolio
  • About
  • News
  • Contact

© 2026 Westlake BioPartners. All Rights Reserved. Privacy Policy